Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1991 Nov-Dec;64(6):583–590.

Taxol: an important new drug in the management of epithelial ovarian cancer.

M Markman 1
PMCID: PMC2589424  PMID: 1687343

Abstract

Taxol, an antineoplastic agent isolated from the Pacific yew, has been demonstrated in three phase 2 clinical trials to have major activity (30 percent overall response rate) in patients with ovarian cancer refractory to cisplatin. The major toxicities associated with the agent are neutropenia (dose-limiting), hypersensitivity reactions, peripheral sensory neuropathy, and cardiac arrhythmias. A recently reported phase 1 trial of the combination of cisplatin and taxol has defined acceptable doses for the two-drug combination to be tested against cisplatin and cyclophosphamide as frontline therapy of advanced ovarian cancer. Taxol has also been examined for intraperitoneal administration in patients with ovarian cancer, with a major pharmacokinetic advantage for peritoneal cavity exposure being demonstrated. Unfortunately, any future development of taxol as an antineoplastic agent in the management of ovarian cancer will be dependent on the finding of an alternative source of the drug, as the current method of obtaining taxol from the bark of the Pacific yew provides insufficient quantities for large-scale clinical use.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Donehower R. C., Rowinsky E. K., Grochow L. B., Longnecker S. M., Ettinger D. S. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987 Dec;71(12):1171–1177. [PubMed] [Google Scholar]
  2. Fan D., Ajani J. A., Baker F. L., Tomasovic B., Brock W. A., Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1469–1476. doi: 10.1016/0277-5379(87)90088-5. [DOI] [PubMed] [Google Scholar]
  3. Gore M. E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990 Feb;36(2):207–211. doi: 10.1016/0090-8258(90)90174-j. [DOI] [PubMed] [Google Scholar]
  4. Grem J. L., Tutsch K. D., Simon K. J., Alberti D. B., Willson J. K., Tormey D. C., Swaminathan S., Trump D. L. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep. 1987 Dec;71(12):1179–1184. [PubMed] [Google Scholar]
  5. Hainsworth J. D., Grosh W. W., Burnett L. S., Jones H. W., 3rd, Wolff S. N., Greco F. A. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 1988 Feb;108(2):165–170. doi: 10.7326/0003-4819-108-2-165. [DOI] [PubMed] [Google Scholar]
  6. Kris M. G., O'Connell J. P., Gralla R. J., Wertheim M. S., Parente R. M., Schiff P. B., Young C. W. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep. 1986 May;70(5):605–607. [PubMed] [Google Scholar]
  7. Laufman L. R., Green J. B., Alberts D. S., O'Toole R., Hilgers R. D., Young D. C., Lin F., Rivkin S. E. Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study. J Clin Oncol. 1986 Sep;4(9):1374–1379. doi: 10.1200/JCO.1986.4.9.1374. [DOI] [PubMed] [Google Scholar]
  8. Legha S. S., Ring S., Papadopoulos N., Raber M., Benjamin R. S. A phase II trial of taxol in metastatic melanoma. Cancer. 1990 Jun 1;65(11):2478–2481. doi: 10.1002/1097-0142(19900601)65:11<2478::aid-cncr2820651114>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  9. Legha S. S., Tenney D. M., Krakoff I. R. Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol. 1986 May;4(5):762–766. doi: 10.1200/JCO.1986.4.5.762. [DOI] [PubMed] [Google Scholar]
  10. Louie K. G., Ozols R. F., Myers C. E., Ostchega Y., Jenkins J., Howser D., Young R. C. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol. 1986 Nov;4(11):1579–1585. doi: 10.1200/JCO.1986.4.11.1579. [DOI] [PubMed] [Google Scholar]
  11. Markman M., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadones L., Lewis J. L., Jr Intraperitoneal therapy in the management of ovarian carcinoma. Yale J Biol Med. 1989 Jul-Aug;62(4):393–403. [PMC free article] [PubMed] [Google Scholar]
  12. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J. L., Jr Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991 Mar;9(3):389–393. doi: 10.1200/JCO.1991.9.3.389. [DOI] [PubMed] [Google Scholar]
  13. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  14. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  15. Omura G. A., Bundy B. N., Berek J. S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Apr;7(4):457–465. doi: 10.1200/JCO.1989.7.4.457. [DOI] [PubMed] [Google Scholar]
  16. Ozols R. F., Young R. C. Ovarian cancer. Curr Probl Cancer. 1987 Mar-Apr;11(2):57–122. doi: 10.1016/s0147-0272(87)80004-1. [DOI] [PubMed] [Google Scholar]
  17. Pater J. L., Carmichael J. A., Krepart G. V., Fraser R. C., Roy M., Kirk M. E., Levitt M., Brown L. B., Wilson K. S., Shelley W. E. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep. 1987 Mar;71(3):277–281. [PubMed] [Google Scholar]
  18. Riondel J., Jacrot M., Nissou M. F., Picot F., Bériel H., Mouriquand C., Potier P. Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice. Anticancer Res. 1988 May-Jun;8(3):387–390. [PubMed] [Google Scholar]
  19. Riondel J., Jacrot M., Picot F., Beriel H., Mouriquand C., Potier P. Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol. 1986;17(2):137–142. doi: 10.1007/BF00306742. [DOI] [PubMed] [Google Scholar]
  20. Rowinsky E. K., Burke P. J., Karp J. E., Tucker R. W., Ettinger D. S., Donehower R. C. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989 Aug 15;49(16):4640–4647. [PubMed] [Google Scholar]
  21. Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. doi: 10.1093/jnci/82.15.1247. [DOI] [PubMed] [Google Scholar]
  22. Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988 Jul 15;48(14):4093–4100. [PubMed] [Google Scholar]
  23. Wani M. C., Taylor H. L., Wall M. E., Coggon P., McPhail A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325–2327. doi: 10.1021/ja00738a045. [DOI] [PubMed] [Google Scholar]
  24. Weiss R. B., Donehower R. C., Wiernik P. H., Ohnuma T., Gralla R. J., Trump D. L., Baker J. R., Jr, Van Echo D. A., Von Hoff D. D., Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990 Jul;8(7):1263–1268. doi: 10.1200/JCO.1990.8.7.1263. [DOI] [PubMed] [Google Scholar]
  25. Wiernik P. H., Schwartz E. L., Einzig A., Strauman J. J., Lipton R. B., Dutcher J. P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. doi: 10.1200/JCO.1987.5.8.1232. [DOI] [PubMed] [Google Scholar]
  26. Wiernik P. H., Schwartz E. L., Strauman J. J., Dutcher J. P., Lipton R. B., Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987 May 1;47(9):2486–2493. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES